Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study

Major Depressive Disorder, Recurrent, in Remission Clinical Trial

Official title:

Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05423275
• Other study ID #: H22-01067
• Status: Recruiting
• Phase: N/A
• Start date: March 13, 2023
• Est. completion date: June 2027

Study information

• Verified date: April 2024
• Source: University of British Columbia
• Contact: Vanessa Evans, BSc
• Phone: 604-822-8102
• Email: vanessa.evans[@]ubc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a "feasibility" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with recurrent MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.

Description:

The purpose of this study is to evaluate the feasibility of a multicentre, randomized, trial of light therapy and negative ion therapy as substitutes for antidepressants for maintenance treatment for patients with recurrent major depressive disorder (MDD).

The study design for this feasibility study mirrors the full LIMIT-D protocol: a 28-week, double-blind (participant and outcome rater) relapse prevention study with 100 participants randomized 1:1 to one of two study treatments, light therapy or negative ion therapy, and assessed for relapse over 28 weeks. Half the study devices are modified to be inactive. After 2 weeks of study treatment, the participant's antidepressant will be tapered and discontinued between Week 2 and Week 8.

Participants are assessed for relapse at each scheduled study visit (every 2 weeks during antidepressant taper until week 8, then every 4 weeks until end of study treatment at Week 28) by blind outcome raters. In addition, they complete an online Personal Health Questionnaire (PHQ-9) self-rated depression symptom scale weekly; if total score is 10 or higher OR the suicide item score is 2 or higher, participants are booked for a relapse-assessment visit and relapse-verification study visit at least 1 week apart. Relapse will be defined as any of the following:

1. MADRS total score 20 or higher for at least 2 consecutive weeks and Diagnostic and Statistical Manual (DSM-5) criteria for major depressive episode at the Relapse-Verification visit.

2. Hospitalization for worsening of depression.

3. Suicidal ideation with intent or plan, or suicidal behaviour.

4. Any change in treatment for depression (e.g., starting an antidepressant).

At each visit, clinician-rated and self-rated symptom, side effect, and functioning measures are completed. The primary feasibility outcome is recruitment rate; secondary feasibility outcomes include adherence to study treatment, successful discontinuation of antidepressants rate, and all-cause dropout rate. Secondary clinical outcomes include relapse rate, time to relapse, adverse events, and safety profiles.

Participants will wear an actigraph at home during the 28-week study treatment period to assess sleep, light and activity/circadian rhythms. There is a final observational visit by Zoom videoconference at Week 52.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnostic and Statistical Manual (DSM-5) criteria for MDD, as determined by the Structured Clinical Interview for DSM-5 (SCID).

• Taking a first-line antidepressant at approved doses (Table 1), with dose unchanged in the past month.

• Participant desire to discontinue antidepressant treatment because of adverse effects or other reasons;

• In remission as defined by score =10 on the clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) at both the screening visit and baseline visit, at least 2 weeks apart.

• Willing and able to complete self-report and online assessments including sufficient fluency in English or French.

Exclusion Criteria:

• Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime). Note that comorbid anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder) will not be excluded if the anxiety disorder is not the primary diagnosis.

• Diagnosis of MDD with seasonal pattern (i.e., seasonal affective disorder, SAD) or with psychotic features (lifetime).

• Significant personality disorder diagnosis [e.g., antisocial] by MINI and clinical assessment.

• High suicidal risk, defined by clinician judgment.

• History of alcohol or substance use disorder, with a severity of at least moderate or severe, within 6 months before screening.

• Significant neurological disorders, head trauma, or other unstable medical conditions.

• Regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers).

• History of severe antidepressant discontinuation effects.

• Retinal disease or other eye condition (e.g., macular degeneration) precluding the use of bright light treatment.

• Use of photosensitizing medication (thioridazine, chloroquine, 8-methoxypsoralen) within 1 week of baseline visit.

• Initiated formal psychotherapy (e.g., cognitive-behavioural therapy) within 3 months of Visit 1, or who plan to initiate psychotherapy during the study.

• Continued use of any other evidence-based treatment for depression.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder, Recurrent, in Remission

Intervention

Device:
• Negative ion therapy
Negative ion generator
• Light therapy
Fluorescent light box

Locations

Country	Name	City	State
Canada	Djavad Mowafaghian Centre for Brain Health	Vancouver	British Columbia

Sponsors (7)

Lead Sponsor	Collaborator
University of British Columbia	Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health, McMaster University, Ontario Brain Institute, Université de Montréal, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Time to relapse	Time to protocol-defined relapse, based on survival analysis	28 weeks
Other	Relapse rate	Rate of relapses, based on survival analysis	28 weeks
Other	Adverse events	Number and severity of adverse events	28 weeks
Other	Serious adverse events	Number of serious adverse events including hypomanic mood switch	28 weeks
Primary	Recruitment rate	The number of participants entered into the study during the recruitment period.	36 months
Secondary	Adherence to study treatment	Percentage of scheduled time that participants use the study treatment	28 weeks
Secondary	Rate of stopping antidepressants	Rate of success in tapering and discontinuing antidepressants	8 weeks
Secondary	All-cause dropout rate	Rate of dropouts from the study for any cause	28 weeks